Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Treosulfan - Medac

Next Previous
Drug Profile

Treosulfan - Medac

Alternative Names: CB-2562; CB-40067; CCRIS 2781; Dihydroxybusulphan; HSDB-6963; NSC 39069; Ovastat; Trecondyv

Latest Information Update: 02 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Medac
  • Developer Center for International Blood and Marrow Transplant Research; Fondazione San Raffaele; Medac; Medexus Pharmaceuticals
  • Class Antineoplastics; Butylene glycols; Mesylates; Small molecules
  • Mechanism of Action Alkylating agents; DNA cross linking agents; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Transplant rejection
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute myeloid leukaemia; Myelodysplastic syndromes; Ovarian cancer
  • Phase II Haematological malignancies; Haemoglobinopathies; Immunodeficiency disorders; Inborn error metabolic disorders; Myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
  • No development reported Renal cell carcinoma; Small cell lung cancer; Solid tumours
  • Discontinued Malignant melanoma

Most Recent Events

  • 02 Dec 2024 NDR#31= No changes, ADS added, keeping line in prereg
  • 02 Dec 2024 Treosulfan is still in preregistration stage for Acute myeloid leukaemia and Myelodysplastic syndromes in USA
  • 12 Jan 2023 Medexus pharmaceuticals announces intention to resubmit NDA to US FDA for Acute myeloid leukaemia and Myelodysplastic syndromes (in combination with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation) in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top